FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically, to recombinant antigens of human desmoglein, and can be used in clinical laboratory diagnostics of pemphigus vulgaris.
EFFECT: invention makes it possible to determine the antigenic specificity of autoreactive antibodies to individual fragments of the extracellular domain of human desmoglein-3 in patients with pemphigus vulgaris by applying a recombinant antigen protein containing antigen proteins of the extracellular domain of human desmoglein-3 and fragments thereof with sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, respectively.
3 cl, 4 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATIONS, CONTAINING ANTIBODIES AGAINST Fas LIGAND, FOR TREATING PEMPHIGUS | 2009 |
|
RU2556818C2 |
| METHOD OF PRODUCING SELECTIVE IMMUNOSORBENT FOR REMOVAL OF ANTIBODIES-IgG TO DESMOGLEIN OF TYPE 3 FROM BLOOD SERUM OF PATIENTS WITH PEMPHIGUS | 2015 |
|
RU2622005C2 |
| ANTIBODIES TO CD38 AND PHARMACEUTICAL COMPOSITIONS BASED THEREON FOR TREATMENT OF AUTOIMMUNE DISEASE MEDIATED BY AUTOANTIBODIES | 2020 |
|
RU2809565C2 |
| APPLICATION OF SELECTIVE IMMUNOSORBENT FOR REMOVAL OF ANTIBODIES TO TYPE 3 DESMOGLEIN FROM BLOOD SERUM OF PATIENTS WITH VESICULAR FEVER | 2016 |
|
RU2627652C1 |
| MEDICATIONS FOR TREATING PEMPHIGUS CONTAINING ANTIBODIES TO Fas-LIGAND | 2008 |
|
RU2558260C2 |
| MEANS AND METHODS FOR DIAGNOSING AND TREATING MULTIPLE SCLEROSIS | 2012 |
|
RU2601298C2 |
| POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS | 2019 |
|
RU2778566C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
| RECOMBINANT DNA ENSURING PRODUCTION OF THE RECOMBINANT PROTEIN COV1 EXHIBITING IMMUNOGENIC PROPERTIES AGAINST SARS-COV-2 VIRUS | 2021 |
|
RU2776484C1 |
